Dedicated to the
Health and Welfare of All Cats
A A A
Font Size
hero-education

Cat Health News Blog

A resource for dedicated cat supporters

Since its start in 2007, Cat Health News has featured the latest information on feline health. The bi-weekly blog is a mix of the most current published research from Winn-funded research and other sources. There are over 875 blog post items and more than 1,000 subscribers through the RSS feed.


icon-blogWinn-funded research is specifically noted by the small green cat.

  • Biochemical Testing for Feline Heart Disease

    Mar 30, 2009
    Zimmering, T. M., F. Meneses, et al. (2009). "Measurement of N-terminal proatrial natriuretic peptide in plasma of cats with and without cardiomyopathy." American Journal of Veterinary Research 70(2): 216-222.

    Nt-proANP is a natriuretic peptide produced in the cardiac muscle cells of the atria. In humans, ANP concentrations are used to distinguish people with chronic heart failure and monitor progression of the disease, survivability, and the efficacy of cardiac interventions. Two recent studies in cats indicated that plasma ANP concentrations were higher in cats with cardiomyopathy (CM) than in healthy cats. This study looked at 43 cats that were divided into three groups: control cats, cats with cardiomyopathy without congestive heart failure (CM without CHF), and cats with cardiomyopathy with congestive heart failure (CM with CHF). All cats had a physical examination, assessment of clinicopathologic variables that included plasma thyroxine concentration, thoracic radiography, and echocardiography. Each cat was assigned to one of the three groups based on results of these findings. A blood sample was taken from all 43 cats for a plasma Nt-proANP concentration using a human ELISA test kit. The first goal of the study was to determine whether Nt-proANP concentrations in cats with CM differ from concentrations in healthy cats. A second goal was to determine if there was a difference in values between cats with CM and no CHF from those cats that had CM with CHF. The results showed significant difference in Nt-proANP concentrations between the control cats that were healthy and the group with CM without CHF. The values were much higher in those cats assessed with CM only. The cats with CM with CHF had even significantly higher concentrations of Nt-proANP than the elevated values noted for the cats with CM and no CHF. Nt-proANP measurement could aid in the assessment of cats with cardiomyopathy and might be useful as a screening marker for the disease. The assay also has the potential for distinguishing between cats with CM without CHF and cats with CM and CHF. [VT]
    >> PubMed Abstract

    Related articles:
    Connolly, D. J., R. J. Soares Magalhaes, et al. (2008). "Circulating natriuretic peptides in cats with heart disease." J Vet Intern Med 22(1): 96-105.
    >> PubMed Abstract

    Biondo, A. W., E. J. Ehrhart, et al. (2003). "Immunohistochemistry of atrial and brain natriuretic peptides in control cats and cats with hypertrophic cardiomyopathy." Vet Pathol 40(5): 501-6.
    >> PubMed Abstract

    NT-proANP natriuretic peptide congestive heart failure cardiomyopathy

    More on cat health:

    Winn Feline Foundation Library
    Find us on Facebook
    Follow us on Twitter
    Pin with us on Pinterest
    Join us on Google+

 

Archives

2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007